Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Poly-ICLC (Hiltonol) Plus Anti-PD1 or Anti-PD-L1 in Unresectable Solid Cancers An Adaptive Phase I/II Clinical Pilot Study

Next Previous
X
Search
Trial Profile

Poly-ICLC (Hiltonol) Plus Anti-PD1 or Anti-PD-L1 in Unresectable Solid Cancers An Adaptive Phase I/II Clinical Pilot Study

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Poly ICLC (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Sponsors Oncovir

    • Most Recent Events

    • 27 Jan 2021 Status changed from active, no longer recruiting to discontinued as recruiting target patients is intermittent making it impracticable to enroll the required study sample. The administrative responsibilities have been met with extraordinary challenges. Current funding does not match the incurring costs.
    • 15 Dec 2020 Status changed from recruiting to active, no longer recruiting.
    • 30 Oct 2019 Planned End Date changed from 31 Aug 2022 to 31 Aug 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top